Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) have partnered to create innovative enzymes aimed at treating orphan and rare diseases. This collaboration combines Selecta's ImmTOR technology, which has shown success in preclinical and clinical trials, with Ginkgo's advanced enzyme discovery capabilities. Under the agreement, Ginkgo could earn up to $85M in cash for milestone achievements and potential royalties on sales, signaling a promising step towards improving therapeutic options for patients with unmet medical needs.
Selecta Biosciences has secured exclusive worldwide rights to Xork, an innovative IgG protease from Genovis, to enhance gene therapy applications and tackle autoimmune diseases. This partnership aims to overcome critical hurdles such as pre-existing immunity and re-treatment limitations associated with AAV gene therapies. Xork demonstrates low cross-reactivity with human antibodies, potentially expanding patient eligibility for gene therapy. The collaboration includes an upfront payment and milestone-based royalties for Genovis.
Selecta Biosciences, a clinical stage biotechnology company, will provide a corporate update and engage in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit on October 27-28, 2021. The presentation is scheduled for 11:00 a.m. EST on October 27. Selecta utilizes its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, enhancing the efficacy of biologic treatments. The company has several programs aimed at enzyme therapies, gene therapies, and autoimmune diseases. For more information, visit selectabio.com.
Selecta Biosciences has entered a strategic licensing agreement with Takeda Pharmaceutical to develop next-generation gene therapies for lysosomal storage disorders using its ImmTOR™ platform. This agreement provides Selecta with an undisclosed upfront payment and potential future earnings of up to $1.124 billion based on development milestones. The collaboration aims to address immunogenicity issues in gene therapy and may enhance treatment options for patients. Selecta is focused on expanding its gene therapy pipeline, leveraging the robust capabilities of Takeda.
On September 21, 2021, Selecta Biosciences, a biotechnology firm utilizing its ImmTOR™ platform, announced its participation in the Cantor Virtual Global Healthcare Conference scheduled for September 27-30, 2021. The company's management will engage in a fireside chat and hold one-on-one investor meetings, with the presentation set for September 27 at 3:20 p.m. EST. An archived webcast will be available on their website following the event. Selecta focuses on developing therapies that mitigate immune responses, with programs targeting gene and autoimmune diseases.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced the appointment of Kevin Tan as Chief Financial Officer. Tan, with extensive experience in gene therapy and rare diseases, is expected to enhance Selecta’s financial strategies. The company anticipates significant milestones, including an IND filing for methylmalonic acidemia and data on an empty capsid study later this year. Selecta leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, aiming to improve treatment options for patients with autoimmune diseases and genetic disorders.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will provide a corporate update at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. Selecta is focused on developing tolerogenic therapies utilizing its ImmTOR™ platform to address unwanted immune responses. The company's pipeline includes enzyme therapies, gene therapies, and treatments for autoimmune diseases.
Selecta Biosciences (NASDAQ: SELB) and Cyrus Biotechnology have announced a collaboration to develop a proprietary IL-2 protein agonist targeting autoimmune diseases. This partnership aims to leverage Selecta's ImmTOR platform and Cyrus's protein engineering capabilities. Preclinical data show synergy between ImmTOR and an IL-2 mutein, enhancing regulatory T cell expansion. The collaboration represents an important step towards innovative biologic therapies. Selecta's strategy includes upfront payments and milestone-based earnings for Cyrus, enhancing its proprietary pipeline.
Selecta Biosciences (NASDAQ: SELB) announced its second quarter 2021 financial results, reporting a net income of $4.6 million, reversing a net loss of $24.1 million in Q2 2020. Revenue reached $19.7 million, attributed to a license agreement with Sobi. With $151.5 million in cash and equivalents, the company has sufficient funds to operate through Q3 2023. Key developments include the resolution of manufacturing issues for SEL-302 and the expectation to file an IND for the gene therapy in MMA during Q3 2021. Topline data for SEL-399 is also anticipated by the end of 2021.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
